Erin Macrae

1.6k total citations · 1 hit paper
20 papers, 1.0k citations indexed

About

Erin Macrae is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Erin Macrae has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Erin Macrae's work include HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (5 papers) and Melanoma and MAPK Pathways (4 papers). Erin Macrae is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Cancer Treatment and Pharmacology (5 papers) and Melanoma and MAPK Pathways (4 papers). Erin Macrae collaborates with scholars based in United States, Canada and Switzerland. Erin Macrae's co-authors include Harold J. Burstein, Hyman B. Muss, Maura N. Dickler, Stephen Johnston, James Khatcheressian, Debra L. Barton, Larissa A. Korde, Hannah Connolly, Rita S. Mehta and Lesley Fallowfield and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Erin Macrae

20 papers receiving 1.0k citations

Hit Papers

Endocrine Therapy for Hormone Receptor–Positive Metastati... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
    2016 446 citations Hope S. Rugo, R. Bryan Rumble et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erin Macrae United States 13 708 445 360 250 92 20 1.0k
Marta Bonotto Italy 18 695 1.0× 443 1.0× 368 1.0× 233 0.9× 67 0.7× 52 1.0k
Frédérique Berger France 19 517 0.7× 323 0.7× 411 1.1× 420 1.7× 71 0.8× 64 1.0k
S-A. Im South Korea 18 799 1.1× 454 1.0× 242 0.7× 324 1.3× 58 0.6× 85 1.1k
Marie‐Paule Sablin France 18 499 0.7× 289 0.6× 354 1.0× 410 1.6× 63 0.7× 50 942
Olga Martínez‐Sáez Spain 11 458 0.6× 343 0.8× 298 0.8× 293 1.2× 48 0.5× 60 832
Amélie Boichard United States 15 550 0.8× 310 0.7× 308 0.9× 311 1.2× 69 0.8× 25 1.0k
Yoshiaki Rai Japan 21 827 1.2× 310 0.7× 421 1.2× 193 0.8× 155 1.7× 55 1.2k
Mikhail Shtivelband United States 15 737 1.0× 709 1.6× 323 0.9× 477 1.9× 93 1.0× 35 1.3k
Janice F. Eakle United States 9 565 0.8× 345 0.8× 265 0.7× 246 1.0× 78 0.8× 22 805
Elisabetta Pietri Italy 15 593 0.8× 200 0.4× 364 1.0× 320 1.3× 87 0.9× 27 909

Countries citing papers authored by Erin Macrae

Since Specialization
Citations

This map shows the geographic impact of Erin Macrae's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Macrae with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Macrae more than expected).

Fields of papers citing papers by Erin Macrae

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Macrae. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Macrae. The network helps show where Erin Macrae may publish in the future.

Co-authorship network of co-authors of Erin Macrae

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Macrae. A scholar is included among the top collaborators of Erin Macrae based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Macrae. Erin Macrae is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Salama, April K.S., Victoria Wang, Erin Macrae, et al.. (2024). Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.. Journal of Clinical Oncology. 42(16_suppl). 3110–3110. 1 indexed citations
2.
Quiroga, Dionisia, Robert Wesolowski, Brooke Benner, et al.. (2024). An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control. 31. 2925668237–2925668237. 3 indexed citations
3.
Parsons, Heather A., Erin Macrae, Hao Guo, et al.. (2021). Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precision Oncology. 5(5). 896–903. 13 indexed citations
4.
Salama, April K.S., Shuli Li, Erin Macrae, et al.. (2020). Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology. 38(33). 3895–3904. 190 indexed citations
5.
Salama, April K.S., Shuli Li, Erin Macrae, et al.. (2019). Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.. Journal of Clinical Oncology. 37(15_suppl). 3002–3002. 7 indexed citations
6.
Wesolowski, Robert, Megan Duggan, Andrew Stiff, et al.. (2017). Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology Immunotherapy. 66(11). 1437–1447. 55 indexed citations
7.
Rugo, Hope S., R. Bryan Rumble, Erin Macrae, et al.. (2016). Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology. 34(25). 3069–3103. 446 indexed citations breakdown →
8.
Lustberg, Maryam B., Tonya Orchard, Xueliang Pan, et al.. (2015). Abstract P1-09-03: Prevention of aromatase Inhibitor (AI)-induced joint symptoms with omega-3 fatty acid supplementation: A randomized placebo-controlled pilot study. Cancer Research. 75(9_Supplement). P1–9. 2 indexed citations
9.
Hicks, Mellissa, Qiuping Hu, Erin Macrae, & James W. DeWille. (2015). Mitogen-activated protein kinase signaling controls basal and oncostatin M-mediated JUNB gene expression. Molecular and Cellular Biochemistry. 403(1-2). 115–124. 7 indexed citations
10.
11.
Seah, Davinia, Inês Vaz-Luís, Erin Macrae, et al.. (2014). Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy. Journal of the National Comprehensive Cancer Network. 12(1). 71–80. 36 indexed citations
12.
Hicks, Mellissa, Qiuping Hu, Erin Macrae, & James W. DeWille. (2014). JUNB promotes the survival of Flavopiridol treated human breast cancer cells. Biochemical and Biophysical Research Communications. 450(1). 19–24. 15 indexed citations
13.
Macrae, Erin, et al.. (2014). Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer Targets and Therapy. 6. 103–103. 39 indexed citations
14.
Berger, Michael, Craig Vargo, Gary Phillips, et al.. (2014). Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care in Cancer. 23(7). 2019–2024. 19 indexed citations
15.
Wesolowski, Robert, et al.. (2014). Treatment-Related Mortality With Everolimus in Cancer Patients. The Oncologist. 19(6). 661–668. 11 indexed citations
16.
Zhao, Meng, Xueliang Pan, Rachel M. Layman, et al.. (2014). A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Investigational New Drugs. 32(6). 1285–1294. 11 indexed citations
17.
Lustberg, Maryam B., Priya Balasubramanian, Brandon Miller, et al.. (2014). Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research. 16(2). R23–R23. 85 indexed citations
18.
Maly, Joseph & Erin Macrae. (2014). Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival. Breast Cancer Basic and Clinical Research. 8. BCBCR.S9032–BCBCR.S9032. 17 indexed citations
19.
Macrae, Erin, et al.. (2007). BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.. Archives of Pathology & Laboratory Medicine. 131(9). 1361–7. 17 indexed citations
20.
Macrae, Erin, et al.. (2007). BRAF Mutations in Melanocytic Lesions and Papillary Thyroid Carcinoma Samples Identified Using Melting Curve Analysis of Polymerase Chain Reaction Products. Archives of Pathology & Laboratory Medicine. 131(9). 1361–1367. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Bonotto Breakdown of academic impact, for papers by Frédérique Berger Breakdown of academic impact, for papers by S-A. Im Breakdown of academic impact, for papers by Marie‐Paule Sablin Breakdown of academic impact, for papers by Olga Martínez‐Sáez Breakdown of academic impact, for papers by Amélie Boichard Breakdown of academic impact, for papers by Yoshiaki Rai Breakdown of academic impact, for papers by Mikhail Shtivelband Breakdown of academic impact, for papers by Janice F. Eakle Breakdown of academic impact, for papers by Elisabetta Pietri
Rankless by CCL
2026